Replies to post #114281 on Biotech Values

[sodrock]

increased sales of Copaxone®. Generic sales in the U.S. were $5,813 million in 2010, up 16% compared to 2009

Wow.. Copaxone is over 50% of US Sales. MNTA is definitely in a pain in TEVA's rearview.